ImmuneOncia Therapeutics, Inc.
ImmuneOncia Therapeutics, Inc., a pioneering biopharmaceutical company headquartered in South Korea (KR), is at the forefront of developing innovative immunotherapies for cancer treatment. Founded in 2015, the company has rapidly established itself within the biotechnology industry, focusing on the discovery and development of novel therapeutic agents that harness the body's immune system to combat malignancies. ImmuneOncia's core offerings include cutting-edge monoclonal antibodies and immune-modulating therapies, distinguished by their unique mechanisms of action and potential to improve patient outcomes. With a strong emphasis on research and development, the company has achieved significant milestones, including successful clinical trials that underscore its commitment to advancing cancer care. As a leader in the immuno-oncology sector, ImmuneOncia Therapeutics continues to make strides in transforming the landscape of cancer treatment.
DitchCarbon Score
How does ImmuneOncia Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
ImmuneOncia Therapeutics, Inc.'s score of 0 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
ImmuneOncia Therapeutics, Inc.'s reported carbon emissions
ImmuneOncia Therapeutics, Inc., headquartered in South Korea (KR), currently does not have available carbon emissions data for the most recent year, nor do they have specified reduction targets or climate pledges. As a result, there is no quantifiable information regarding their Scope 1, 2, or 3 emissions. In the absence of specific emissions data, it is important to note that many companies in the biopharmaceutical sector are increasingly focusing on sustainability and climate commitments. This often includes initiatives aimed at reducing their carbon footprint and enhancing environmental responsibility. ImmuneOncia Therapeutics may be engaging in similar efforts, although specific details are not provided. For stakeholders and environmentally conscious investors, it is crucial to monitor the company's future disclosures regarding emissions and climate strategies to assess their commitment to sustainability.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
ImmuneOncia Therapeutics, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
